Stephens & Co. Initiates Coverage On Inovio Pharmaceuticals with Overweight Rating, Announces Price Target of $20
Portfolio Pulse from Benzinga Newsdesk
Stephens & Co. analyst Sudan Loganathan initiates coverage on Inovio Pharmaceuticals (INO) with an Overweight rating and a price target of $20.
May 14, 2024 | 10:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Inovio Pharmaceuticals receives an Overweight rating from Stephens & Co. with a price target of $20, indicating a positive outlook on the stock's future performance.
The initiation of coverage by Stephens & Co. with an Overweight rating and a high price target suggests a strong bullish outlook for Inovio Pharmaceuticals. This endorsement by a reputable analyst could lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100